Novartis’s Canakinumab Fails In COVID-19 Pneumonia Patients

Dexamethasone Remains Only Proven Therapy In Severe Disease

Drug fails to save lives in study and follows disappointments from Roche and Regeneron/Sanofi's IL-6 inhibitors.

Basel, Switzerland - 27 August, 2016: sign on the wall of a Novartis building. Novartis International AG is a Swiss pharmaceutical company based in Basel, Switzerland.
The trial aimed to help hospitalized patients not yet on mechanical ventilation but failed to show an impact on mortality rates. • Source: Archive

Novartis’s anti-inflammatory drug canakinumab has failed to cut deaths in a trial involving critically ill COVID-19 patients with pneumonia and cytokine release syndrome (CRS).

The CAN-COVID study involved 454 patients at multiple centers across the US, Russia and Europe who were hypoxic but not...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip